Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension

Abstract There was no structured method for safely transition from parenteral prostanoids to oral medication. We enrolled 37 idiopathic/hereditary pulmonary arterial hypertension patients receiving triple combination therapy including parenteral prostanoids into structured transition program to oral...

Full description

Bibliographic Details
Main Authors: Yuichi Tamura, Asuka Furukawa, Yudai Tamura, Kenta Yamada, Hirohisa Taniguchi, Keiichi Fukuda, Akio Kawamura, Toru Satoh
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Pulmonary Circulation
Subjects:
Online Access:https://doi.org/10.1002/pul2.12058
Description
Summary:Abstract There was no structured method for safely transition from parenteral prostanoids to oral medication. We enrolled 37 idiopathic/hereditary pulmonary arterial hypertension patients receiving triple combination therapy including parenteral prostanoids into structured transition program to oral selexipag. Four (10.8%) patients successfully transitioned under the protocol, and all of them presented long‐term safety.
ISSN:2045-8940